epocrates

Drug Updates: Week of February 2, 2026

February 9, 2026

Here's a quick roundup of last week’s new drug monographs and updates.

New Brand Monograph

Oziltus (denosumab-mobz)

• Indications: 1) solid tumor-associated bone metastases in adult patients; 2) multiple myeloma-associated skeletal-related event prevention in adult patients; 3) unresectable giant cell tumor of bone in adult and pediatric adolescents with skeletal maturity; and 4) malignant hypercalcemia in adult patients
• Formulation: INJ for subcutaneous use

New Diagnostic Monograph

R‑Gene 10 (arginine)

• Indication: diagnosis of growth hormone deficiency in adult and pediatric patients
• Formulation: IV injection

New and Expanded Indications

Cablivi (caplacizumab-yhdp)

• New: acquired thrombotic thrombocytopenic purpura in pediatric patients 12 years and older
• Existing: acquired thrombotic thrombocytopenic purpura in adult patients
• Read more: Cablivi OK’d for acquired thrombotic thrombocytopenic purpura in pediatric patients

Idacio (adalimumab-aacf)

• New: 1) moderate-severe hidradenitis suppurativa in pediatric patients 12 years and older; and 2) uveitis in pediatric patients 2 years and older
• Existing: 1) moderate-severe hidradenitis suppurativa in adult patients; and 2) uveitis in adult patients

Formulation Update

Yesafili (aflibercept-jbvf)

• New: INJ (pre-filled syringe): 2 mg per 0.05 mL
• Existing: INJ (vial): 2 mg per 0.05 mL

First-time Generic

estrogens, conjugated

• Indications: 1) moderate-severe menopausal vasomotor symptoms in adult patients; 2) moderate-severe menopausal vulvovaginal atrophy in adult patients; 3) female puberty induction in pediatric patients 11 years and older; and 4) various other
• Equivalent brand: Premarin